Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Shape Memory Medical, Inc.
- Trial code
- NCT04227054
- Record updated
- 22 December 2025
- Original description
To determine the safety and efficacy of IMPEDE-FX Embolization Plug and/or IMPEDE-FX Rapid Fill to fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft.Read full original descriptionShow less
Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks - A Prospective Single Center Safety Study
To determine the safety and efficacy of IMPEDE-FX Embolization Plug and/or IMPEDE-FX Rapid Fill to fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft.
Inclusion: ≥18 years of age; A candidate for elective EVAR of an infrarenal aortic aneurysm ≥5.5 cm in diameter in men and ≥5.0 cm in women.
Exclusion: Concomitant iliac artery ectasia or aneurysm (common iliac artery diameter >24 mm); Planned use of embolic devices other than the investigational product to embolize the AAA sac; Vascular disease and/or anatomy that preclude the safe access and positioning of a catheter to deliver the investigational product into the AAA sac; Long-term (>6 months prior to the procedure) use of direct oral anticoagulant or any vitamin K antagonist anticoagulant use; Cerebrovascular accident within 3 months prior to the procedure; Myocardial infarction and/or major heart surgery within 3 months prior to the procedure; Pregnant or a lactating female. For females of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the study; Ruptured, leaking, or mycotic (infected) aneurysm; Aneurysmal disease of the descending thoracic aorta; Coagulopathy or uncontrolled bleeding disorder; Known hypersensitivity or contraindication to platinum, iridium, or polyurethane; A condition that inhibits radiographic visualization during the implantation procedure; History of allergy to contrast medium that cannot be managed medically; Uncontrolled co-morbid medical condition, including mental health issues, that would adversely affect participation in the study; Serum creatinine level >2.5 mg/dL; Life expectancy of <2 years post-procedure; An inability to provide informed consent; Enrolled in another clinical study; Patent AAA sac feeding vessels (within the sac) >4 mm in diameter; Volume of AAA sac to be filled after stent graft placement <30 mL or >135 mL, based on pre-procedure CTA (i.e. aortic flow volume exclusive of stent graft volume); Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis, Cook Zenith Flex AAA Endovascular Graft, Medtronic Endurant II Stent Graft, or Endologix Ovation Alto Abdominal Stent Graft System to treat the AAA; Planned use of the chosen stent graft outside its instructions for use (IFU); Planned use of fenestrated or chimney stent grafts; Study participants in which stent graft placement is abandoned for any reason, and/or in which the investigator decides, during the course of the stent graft placement, that the study procedure may not be appropriate; Atrial fibrillation that is not well rate controlled; Unable or unwilling to comply with study follow-up requirements; Prisoner or member of other vulnerable population.